The beneficial effects of isothiocyanate-based compounds, as well as their safety, have been shown in neuropathological disorders, such as neuropathic pain. Aim of the present work was to study the efficacy of the glucosinolate glucoraphanin 
referred to SFN) is the ITC released by the enzymatic action of plant-endogenous myrosinase (β-thioglucoside glucohydrolase; E.C.
3.2.1.147; MYR) or by the microflora on glucoraphanin (GRA), a glucosinolate present especially in Tuscan black kale seeds (De Nicola, Rollin, Mazzon, & Iori, 2014) . The interest in these phytochemicals escalated following the discovery of their cytoprotective properties against oxidative stress (Guerrero-Beltrána, Calderón-Oliver, Pedraza-Chaverri, & Chirino, 2012) . In the last years, beneficial effects of these compounds in models of neurological diseases, as well as their safety, have been shown (Galuppo et al., 2013; Giacoppo et al., 2014) . In fact, like SFN, also other ITC-based compounds show protective effects in models of nervous tissue injury (Wang et al., 2012) and neuropathic pain development (Negi, Kumar, & Sharma, 2011) .
Among the different mechanisms of action, which may account for the different biological effects of ITCs, the release of hydrogen sulphide (H 2 S) has been recently reported: indeed, the ITC moiety was recognized as an original H 2 S-releasing chemical group . Noteworthy, significant H 2 S-releasing properties have been also exhibited by many natural ITCs from Brassicaceae species, closely related with SFN, from a structural point of view . Consistently, the H 2 S release and the activation of Kv7 potassium channels were demonstrated to be involved in the antihyperalgesic effect of ITC-based compounds (Di Cesare Mannelli et al., 2017) . Although many of the health benefits showed by GRA and SFN are similar to that attributed to H 2 S or other H 2 S-donating ITCs , the role of this gasotransmitter in their pharmacological effects needs to be further evaluated. This evidence could bring to light a new mechanism of action for these phytochemicals, which is not only attributable to their well-known antioxidative (Nrf2/ARE pathway; Xu et al., 2006) and anti-inflammatory proprieties (NF-kB pathway; Heiss, Herhaus, Klimo, & Bartsch, 2001) . The aim of the present study was to evaluate the effect of acute and repetitive GRA and SFN administrations on neuropathic pain induced by oxaliplatin in mice. In this contest, the pharmacodynamic involvement of H 2 S and Kv7 potassium channels in their effect was investigated.
| MATERIAL AND METHODS

| Amperometric determination of H 2 S release
The evaluation of the potential H 2 S releasing properties of GRA and SFN was carried out by an electrochemical approach with an Apollo-4000 amperometric detector (WPI) and H 2 S-selective mini-electrodes, as previously described . Briefly, a "PBS buffer 10X" was previously prepared (NaH 2 PO 4 ·H 2 O 1.28 g, Na 2 HPO 4 ·12H 2 O 5.97 g, NaCl 43.88 g in 500-ml H 2 O) and stocked at 4°C. For the experiments, the assay buffer was obtained by 1:10 dilution of the PBS buffer 10X with distilled water. The pH was adjusted to 7.4.
The H 2 S-selective mini-electrode was immerged in 10-ml assay buffer at room temperature. After the recovery of a stable baseline, 100 μl of a DMSO solution of GRA or SFN was added (the final concentration of the tested compounds was 1 mM; the final concentration of DMSO in the AB was 1%). The possible formation of H 2 S was observed for 20 min. Preliminary measurements showed that DMSO 1% did not interfere with the amperometric recording. In selected experiments, L-cysteine (4 mM) was added before the addition of GRA or SFN. The relationships between the amperometric currents (detected in picoampere) and the matched concentrations of H 2 S were evaluated by suitable calibration curves with the H 2 S-generating salt NaHS (1, 3, 5, and 10 μM) at pH 4.0.
| Animals
Male CD-1 albino mice (Envigo, Varese, Italy) weighing approximately 22-25 g at the beginning of the experimental procedure were used. 
| Compound administrations
GRA and enantiopure R-SFN were purified from Tuscan black kale seeds at the Bologna laboratory (CREA-AA; previously CRA-CIN) according to an establish method . These compounds were dissolved in saline solution for subcutaneous (sc) administration and in carboxymethyl cellulose 1% for oral (po) administration. Compounds were acutely administered as follows. The doses of GRA were chosen on the basis of previously published H 2 S releasing and antinociceptive properties of synthetic ITCs (Di Cesare Mannelli et al., 2017; Martelli et al., 2013): 4.43, 13.31, 39.93 
| Cold plate test
The animals were placed in a stainless steel box ( 
| Statistical analysis
The curves relative to the progressive increase of H 2 S versus time,
following the incubation of the tested compounds, were analysed by a computer fitting procedure (GraphPad Prism 5.0) and expressed as mean ± S.E.M. with at least five different curves performed for each compound. Behavioural measurements were performed on 16 mice for each treatment carried out in two different experimental sets.
Investigators were blind to all experimental procedures. Results were expressed as mean ± S.E.M. The analysis of variance of data was performed by one-way analysis of variance, and a Bonferroni's significant difference procedure was used as post hoc comparison. p values of less than 0.05, 0.01, or 0.001 were considered significant. Data were analysed using the "Origin 9" software (OriginLab, Northampton).
| RESULTS
As already observed for other natural ITCs , SFN exhibited significant L-cysteine-dependent release of H 2 S. In particular, the incubation of SFN 1 mM led to a slow formation of H 2 S, reaching a steady-state concentration of about 0.75 μM; in the absence of L-cysteine, the H 2 S generation from SFN was almost completely negligible. Only in the presence of this amino acid, the incubation of SFN with L-cysteine led to the formation of H 2 S (Figure 1a) . Surprisingly, the glucosinolate GRA showed a similar behaviour: in the presence of L-cysteine, the incubation of GRA 1 mM led to a slow formation of H 2 S, reaching a steady-state concentration of about 1 μM (Figure 1b) , whereas in the absence of L-cysteine, the H 2 S generation from both SFN and GRA was almost completely negligible (Figure 1a and 1b) . The effect of the subcutaneous and orally repeated treatment with GRA and SFN on chemotherapy-induced neuropathic pain in mice is shown in Figure 3a and 3b, respectively. Repeated treatment consisted of a daily administration following the same protocol ) and so to prevent its pharmacological activities. Both Figure 3a and 3b show the acute antihyperalgesic effect induced by GRA (13.31 μmol kg −1 sc) and SFN (4.43 μmol kg −1 sc) in oxaliplatin-treated animals. The co-administration with Hb (3.1 μmol kg −1 sc) was able to fully prevent the antineuropathic efficacy of both GRA and SFN.
In fact, the pain threshold of animals treated with GRA and SFN in mixture with Hb was not significantly different from that of oxaliplatin + vehicle-treated animals (Figure 4a and 4b) . The suppression of the pain-relieving efficacy of GRA and SFN mediated by Hb can be further appreciated considering the resulting AUC (Figure 4b ).
To demonstrate the involvement of Kv7 potassium channel in the antineuropathic effect of GRA and SFN, a selective Kv7 blocker, XE991, was administered 15 min before these phytochemicals. In Figure 5a and 5b was shown the effect induced by the single administration of GRA (13.31 μmol kg −1 po) and SFN 
| DISCUSSION
The development of neuropathic pain is a severe dose-limiting side effect of commonly used chemotherapeutic agents (Ward et al., 2014) . Antidepressants and antiepileptics, currently considered the elective therapy for these types of pain, show a low efficacy and several negative side effects (Cruccu & Truini, 2017) . It is thus clear that, for the management of this type of pain, innovative, safe, and effective treatments still have to be developed.
Recently, it has been observed that synthetic and natural ITC compounds are efficient in relieving neuropathic pain induced in animals by chemotherapic agents, as paclitaxel and oxaliplatin (Di Cesare Mannelli et al., 2017) . In line with the previous data, the present results show that the natural enantiopure isothiocyanate R-SFN and its precursor GRA effectively reduce the hypersensitivity to a cold non-noxious stimulus (allodynia-related measurement) after acute administration in oxaliplatin-treated animals.
GRA resulted slightly less effective by subcutaneous administration than by oral administration, suggesting that the gastroenteric metabolism enhances the bioavailability of the active compound (Fahey et al., 2015) .
This evidence is in line with the fact that GRA frequently is bioactivated with MYR before the administration in vivo and in vitro (Galuppo et al., 2013) , suggesting that the responsible for most of the pharmacological properties showed by these phytochemicals is actually SFN. This point was strengthened by the present findings, because SFN resulted 10 fold more potent than GRA.
In addition to the acute effect on neuropathic pain, both GRA and SFN, when repeatedly administered in the animals starting from the first day of oxaliplatin treatment, resulted able to reduce the development of neuropathy. Besides, both GRA and SFN showed beneficial neuroprotective effects in different conditions of central and peripheral nervous system damage (Giacoppo et al., 2014) . Particularly, the treatment with the glucosinolate seems able to shot down the astrocytes activation in the spinal cord, condition that results strongly associated with the establishment and the persistence of neuropathic pain (Di Cesare Mannelli et al., 2014; Galuppo et al., 2013) .
In the years, many mechanisms of action were attributed to SFN. Among them, the most studied were the antioxidant and anti-inflammatory effects (Guerrero-Beltrána et al., 2012; Heiss et al., 2001) . Indeed SFN has been described as a strong enhancer of Nrf2-ARE pathway (Negi et al., 2011) and a suppressor of NF-kB signalling pathway (Heiss et al., 2001 ).
However, although the antioxidative properties could explain the neuroprotective effect showed by the repeated treatments both with SFN and GRA (Areti, Yerra, Naidu, & Kumar, 2014) , it is unlikely this mechanism could be responsible for the acute antihyperalgesic effect showed by these molecules. In this regard, our results are consistent with the previous findings demonstrating that synthetic and natural ITCs act as H 2 S-releasing compounds Di Cesare Mannelli et al., 2017) . In fact, the amperometric recordings showed that actually SFN shows a H 2 S-donor profile.
Surprisingly, even GRA showed an almost equivalent behaviour of H 2 S-releasing agent. The role of H 2 S in the analgesic effects of both SFN and GRA seems to be strongly supported by the observation that the H 2 S-binding molecule Hb (Mishanina et al., 2015) ; a) and SFN (4.43 μmol kg −1 ; b) were dissolved in 1% carboxymethyl cellulose and saline solution, respectively, for oral and subcutaneous administration. Repeated treatment consisted of a daily administration following the same protocol described for oxaliplatin from the first up to the 14 th day. Behavioural tests were performed on Days 8 and 15, 24 hr after the treatment.^^p < 0.01 versus vehicle + vehicle treated mice; *p < 0.05 and **p < 0.01 versus oxaliplatin + vehicle-treated mice Noteworthy, the effects displayed by this gasotransmitter showed a bell-shaped dose-dependence both in vivo and in vitro (Di Cesare Mannelli et al., 2017) . It is thus deductible that the kinetic of H 2 S release from H 2 S donor compounds is a paramount factor for their pharmacological properties. Regarding this, the H 2 S slow-releasing capacity was demonstrated to be an important feature for H 2 S donors . In fact, in vitro, low concentrations of H 2 S donors resulted beneficial, whereas the elevation of H 2 S concentrations beyond a certain concentration range can become cytotoxic, prooxidant, and suppresses mitochondrial electron transport (Szabo et al., 2014) . Similarly, in vivo, H 2 S is effective in relieving neuropathic pain at very low doses, but by increasing the dose, the effect decreases (Di Cesare Mannelli et al., 2017) .
A further proof is the fact that slow H 2 S donors, such as GYY4137, are often more effective than rapid donors, such as NaHS, suggesting that long-lasting generation of relatively lower concentrations of H 2 S can be preferable (Li et al., 2008) , as this gas is able to easily reach the blood stream and then its molecular targets on the cell membrane, inside the cytosol or in intracellular organelles (Wallace & Wang, 2015) . In the past, some series of different H 2 S pro-drugs were developed (Zheng, Ji, Ji, & Wang, 2015) often obtaining a limited control of gas release. In this context, GRA, being hydrolysable in vivo (Fahey et al., 2015) , could be usefully employed for therapeutic purposes. In fact, even though SFN seems to be the responsible for the antihyperalgesic effect showed by GRA, the latter showed a better kinetic profile after the administration in the animals, with a more prolonged effect. Therefore, considering that GRA is more stable than SFN especially in solution (Fahey et al., 2017) and that GRA could mediate a slow release of SFN and consequently of H 2 S in vivo, it could be more advantageous to use the intact glucosinolate instead of the ITC, even though the latter results more potent.
Looking further into the mechanisms of action with which the ITCs can influence pain perception, it is noteworthy that the activation of Kv7 potassium channels may have a relevant role, among the pleiotropic mechanisms of action played by H 2 S in different biological systems (Martelli et al., 2013) . Consistently, we found that GRA and SFN, as other ITC-based compounds, can modulate the activity of the voltage-gated Kv7 potassium channels (Di Cesare Mannelli et al., 2017) . This type of potassium channels plays a pivotal role in pain modulation (Nodera, Spieker, Sung, & Rutkove, 2011) . In fact, Kv7 channels activators, as retigabine and flupirtine show antihyperalgesic effects that were mainly related to the suppression of sensitive neurons excitability (Sittl, Carr, Fleckenstein, & Grafe, 2010) . Given that the abnormal painful signalling during neuropathic condition is due to an overexpression and overactivation of ion channels and receptors in neurons, probably, the H 2 S released from GRA and SFN could act on neuropathic pain by activating Kv7 channels along pain pathways. This initial consideration was confirmed by the present data showing that the pain-relieving effect of both GRA and SFN is abolished by pretreating the animals with the Kv7 channel blocker, XE991.
In conclusion, the present study demonstrates that natural GRA chemotherapic treatment. On the other side, these compounds could be acutely used to give an immediate pain relief.
Finally, it is also important to consider that these compounds are largely present in many common edible plant belonging to Brassiceae family, rising the interesting possibility to use foods and supplements enriched with glucoraphanin and sulforaphane to support and enhance pain therapies. It might also allow an easier and safer translation to clinical application. To this end, the H 2 S-release kinetic of these compounds could be further investigated in order to improve their pharmacokinetic profile and, therefore, to maximizing their pharmacological effects.
